US FDA approves Gilead's Cayston for cystic fibrosis
This article was originally published in Scrip
Executive Summary
The US FDA has approved Gilead Sciences' inhaled antibiotic Cayston (aztreonam for inhalation solution) for the improvement of respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa.